https://turoeducate.turocrates.ai/cases/77d2288c-8e9b-4eaf-be87-cae5ad4cb0c7 please look into this histology and describe the image and give diagnosis
Reading Web Page
https://turoeducate.turocrates.ai/cases/77d2288c-8e9b-4eaf-b…
The page requires authentication and couldn't be accessed directly. The URL points to a case on the Turo Educate platform, which is a login-protected system - so I can't retrieve the image from that link.
To help you with the diagnosis, please:
- Take a screenshot of the histology image and upload it here, OR
- Copy/paste the image directly into the chat
Once I can see the actual histology image, I will:
- Describe all visible microscopic features (cell types, architecture, staining patterns, any notable findings)
- Provide a differential diagnosis
- Give the most likely diagnosis with reasoning
Please share the image directly and I'll give you a full analysis right away.
IMG_1517.jpg
+2 more
39 year old female TAH+BSO done for subserous fibroid posterior wall of uterus. Sections from left ovary. This is the question and images
analyse_media
analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
angiosarcoma ovary primary histology
Reading File
Reading Article
PMID: 33509230
Reading Article
PMID: 40788747
Reading File
I now have all the information needed for a comprehensive analysis. Here is the full report:
Histopathology Report - Left Ovary
Clinical Details: 39-year-old female. TAH+BSO performed for subserous fibroid (posterior wall uterus). Sections from left ovary (incidental/additional finding).
Image Descriptions
Image 1 (Low Power - Whole Section View)
- The entire tissue section shows a lobulated, nodular architecture replacing normal ovarian parenchyma
- Large geographic zones of coagulative necrosis dominate the section - vast eosinophilic (pink), acellular, amorphous areas where nuclear detail is lost (karyolysis/karyorrhexis)
- A prominent large, rounded, thrombosed vessel in the upper-central region shows homogeneous dark-pink material filling the lumen with lines suggesting early organization
- Between the necrotic zones, there are basophilic cellular bands representing residual viable tumor with hemorrhage
- Extensive extravasated erythrocytes throughout the tissue
- Irregular white cleft-like spaces likely represent retraction artifact or areas of liquefactive change
Image 2 (Medium-High Power)
- Highly atypical cells showing marked pleomorphism - spindle cells, epithelioid cells, and bizarre multinucleated giant cells mixed together
- Cells are arranged in disorganized, cohesive sheets and dissecting cords that line irregular, blood-filled spaces
- The most striking feature: highly atypical malignant cells directly lining anastomosing, irregular vascular channels - some cells project into the lumina (vasoformative pattern)
- Nuclear features: hyperchromatic, coarsely clumped chromatin, large prominent eosinophilic macronucleoli, irregular thickened nuclear membranes
- Large lakes of extravasated red blood cells dissecting between tumor cells (not contained within well-formed vessels)
- Fibrocollagenous stroma with areas of myxoid change
- Scattered lymphocytes and occasional neutrophils in the background
Image 3 (High Power)
- Marked nuclear atypia with anisokaryosis - extreme variation in nuclear size and shape
- Bizarre multinucleated tumor giant cells with multiple dark nuclei
- Atypical mitotic figures including multipolar mitoses - hallmark of high-grade malignancy
- Some cells show vacuolated cytoplasm with intracytoplasmic lumina occasionally containing trapped erythrocytes - a highly characteristic feature of endothelial differentiation
- Cytoplasm is moderately abundant, eosinophilic, and glassy in some cells
- No keratin pearls, no intercellular bridges - squamous differentiation excluded
- Background of extravasated RBCs and loose collagenous stroma
Diagnosis
Primary Ovarian Angiosarcoma (Epithelioid/High-Grade)
Diagnostic Reasoning
The combination of features is diagnostic:
| Feature | Present in this case |
|---|---|
| Anastomosing, irregular vascular channels | Yes |
| Malignant endothelial cells lining blood spaces | Yes |
| Intracytoplasmic lumina with trapped RBCs | Yes |
| Marked nuclear pleomorphism + giant cells | Yes |
| Atypical mitoses | Yes |
| Extensive hemorrhage and necrosis | Yes |
| Destruction of normal ovarian architecture | Yes |
This pattern - malignant cells forming anastomosing vascular channels and directly lining blood-filled spaces with intracytoplasmic vacuoles containing erythrocytes - is the hallmark of angiosarcoma (malignant endothelial tumor).
Differential Diagnoses (Excluded)
- Yolk sac tumor - would show Schiller-Duval bodies, AFP+; no vasoformative pattern
- Clear cell carcinoma - hobnail cells, CK/PAX8+; no endothelial lining pattern
- Undifferentiated pleomorphic sarcoma / MFH - no vasoformative channels; storiform pattern
- Metastatic carcinoma - cohesive glands/nests, epithelial markers positive
- Epithelioid hemangioendothelioma - lower grade, myxohyaline stroma, less atypia
Recommended Immunohistochemistry (to confirm)
| Marker | Expected in Angiosarcoma |
|---|---|
| CD31 | Strongly positive (most sensitive endothelial marker) |
| ERG | Positive |
| Fli-1 | Positive |
| CD34 | Focally positive |
| D2-40 | Can be positive |
| CK / PAX8 | Negative (excludes carcinoma) |
| S-100 | Negative |
| Ki-67 | High (~40-60%) |
Per a 2021 case report in J Ovarian Research (PMID: 33509230) and a 2025 Indian J Cancer report (PMID: 40788747), primary ovarian angiosarcoma is exceedingly rare (~1 in 1,000,000 malignant ovarian tumors). It can present as a pure primary tumor or in a background of teratoma/carcinosarcoma. IHC confirmation with CD31, ERG, and Fli-1 positivity with negative epithelial markers is required.
Clinical Significance
- Primary ovarian angiosarcoma is highly aggressive with poor prognosis
- Principal metastatic route is hematogenous
- Requires staging, omentectomy, and pelvic peritoneal assessment
- Adjuvant treatment options include paclitaxel/carboplatin-based chemotherapy +/- targeted therapy (anti-VEGF) and immunotherapy
- Multidisciplinary tumor board discussion is essential
- Robbins, Cotran & Kumar Pathologic Basis of Disease, Vascular Tumors section, p.489
- Robbins & Kumar Basic Pathology, Tumors chapter
- Ye H et al., J Ovarian Res 2021 [PMID: 33509230]
- Kumar A et al., Indian J Cancer 2025 [PMID: 40788747]
This has cytotrophoblast and syncitio trophoblast
Finding Sources
Finding Sources
Reading File
Reading File
Thank you for that critical correction. With cytotrophoblasts and syncytiotrophoblasts identified, the diagnosis is clear:
Revised Diagnosis: Choriocarcinoma of the Ovary (Non-gestational Germ Cell Type)
Why This Changes Everything
What I initially interpreted as "malignant endothelial cells lining vascular channels" are actually the two defining trophoblastic cell populations:
| Cell Type | What You See in the Images |
|---|---|
| Cytotrophoblasts | Mononuclear, polygonal cells with pale/clear cytoplasm, distinct cell membranes, single vesicular nuclei - the "inner" cell layer |
| Syncytiotrophoblasts | Large, multinucleated giant cells with abundant dense eosinophilic cytoplasm - the bizarre giant cells I noted at high power |
This dimorphic trophoblastic pattern - cytotrophoblasts + syncytiotrophoblasts in a background of hemorrhage and necrosis - is the textbook hallmark of choriocarcinoma.
Re-interpreting the Images
Image 1 (Low power):
- Geographic coagulative necrosis and hemorrhage - classic in choriocarcinoma (tumors often outgrow blood supply)
- The "thrombosed vessel" = likely a hemorrhagic/necrotic zone
- Nodular masses of trophoblastic tissue interspersed with blood lakes
Image 2 (Medium-high power):
- Sheets of cytotrophoblasts (smaller, mononuclear cells) intermingled with
- Syncytiotrophoblastic giant cells (large, multinucleated) directly bordering hemorrhagic spaces
- This "lining of blood spaces" by trophoblasts is characteristic - syncytiotrophoblasts physiologically invade vessels
Image 3 (High power):
- The intracytoplasmic vacuoles = actually cytoplasmic vacuolation of cytotrophoblasts
- Multinucleated giant cells = syncytiotrophoblasts (NOT tumor giant cells of sarcoma)
- Marked pleomorphism and atypical mitoses are expected in choriocarcinoma
Classification in This Context
Since this is a 39-year-old female with no history of pregnancy at this site, and this was an ovarian tumor:
Primary Non-gestational Choriocarcinoma of the Ovary (Germ Cell Tumor)
However, given her age and the TAH+BSO context, gestational choriocarcinoma metastatic to the ovary must also be excluded by:
- Careful history of recent pregnancy/abortion/mole
- Serum beta-hCG level (will be markedly elevated in both)
- Histologically both are identical - clinical context distinguishes them
Per Berek & Novak's Gynecology: "Pure nongestational choriocarcinoma of the ovary is extremely rare. Histologically, it has the same appearance as gestational choriocarcinoma metastatic to the ovaries."
Recommended Workup
IHC Panel:
| Marker | Expected |
|---|---|
| beta-hCG | Strongly positive in syncytiotrophoblasts |
| PLAP | Positive |
| CD10 | Positive in cytotrophoblasts |
| CK (AE1/AE3) | Positive |
| PAX8 | Negative |
| AFP | Negative (helps exclude mixed germ cell tumor with yolk sac component) |
| OCT4 / SALL4 | May be positive |
Serum markers: beta-hCG (markedly elevated), AFP (to rule out mixed germ cell)
Management
- Staging: CT chest/abdomen/pelvis for metastases (lung, liver, brain are common sites)
- Chemotherapy: EMA-CO regimen (for gestational) OR BEP (bleomycin, etoposide, cisplatin) for non-gestational germ cell
- MAC regimen (methotrexate, actinomycin-D, cyclophosphamide) also reported
- Prognosis: Poor in non-gestational type; gestational choriocarcinoma has far better chemo-sensitivity
- Monitor: Serial beta-hCG levels as tumor marker for response
- Berek & Novak's Gynecology, Choriocarcinoma of the Ovary, p.2395
- Robbins & Kumar Basic Pathology, Table 17.4 - Ovarian Germ Cell Neoplasms, p.699-700
How to distinguish gestational and non gestational
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
gestational non-gestational choriocarcinoma ovary differentiation diagnosis
Reading File
Reading Article
PMID: 39246853
Reading File
Here is a complete, structured answer:
Distinguishing Gestational vs. Non-Gestational Choriocarcinoma
Histologically, both are identical - both show the same dimorphic cytotrophoblast + syncytiotrophoblast pattern with hemorrhage and necrosis. Distinction depends on clinical, genetic, and ancillary methods.
1. Clinical History (First Step)
| Feature | Gestational | Non-Gestational |
|---|---|---|
| Preceding pregnancy | Yes - recent molar pregnancy, abortion, ectopic, or term pregnancy | No antecedent pregnancy; or arises de novo |
| Age | Any reproductive age; often follows mole | Usually younger (<20 yrs for pure germ cell); but can be any age |
| Primary site | Uterus most common; ovary = metastasis from uterus | Ovary is the primary site |
| Associated tumor | Uterine/ectopic site identified | May arise within teratoma, dysgerminoma, or mixed germ cell tumor |
| Response to chemo | Near 100% remission with methotrexate-based regimens (EMA-CO) | Much poorer response; needs BEP (germ cell regimen) |
2. The Gold Standard: DNA Genotyping / Short Tandem Repeat (STR) Analysis
This is the most definitive method:
| Gestational | Non-Gestational | |
|---|---|---|
| Genetic origin | Contains paternal alleles (it IS a conception product - an allograft in the mother) | Only maternal alleles present (purely derived from patient's own genome) |
| Method | PCR-based STR/microsatellite polymorphism analysis of tumor DNA vs. patient's blood DNA | Same method |
| Result | Tumor DNA shows extra alleles not present in patient's blood = paternal contribution confirmed | Tumor DNA is identical to patient's constitutional DNA - no paternal contribution |
This is critical because a 39-year-old woman with gestational choriocarcinoma could have had a prior pregnancy/molar pregnancy years ago, and the tumor could represent late recurrence.
3. Morphological Clues (on H&E - not definitive alone)
| Feature | Gestational (favors) | Non-Gestational (favors) |
|---|---|---|
| Associated elements | No other germ cell components | May contain teratoma, yolk sac tumor, dysgerminoma |
| Uterine lesion | Often concurrent uterine lesion or scar | No uterine primary |
| Villi | Chorionic villi may be present in early cases | Absent (no villous structures) |
| Intermediate trophoblast | More prominent implantation site intermediate trophoblast | Less prominent |
4. Immunohistochemistry
| Marker | Gestational | Non-Gestational |
|---|---|---|
| beta-hCG | Strongly positive (both) | Strongly positive (both) |
| p57KIP2 | Negative in complete mole (paternally imprinted gene - absent when no maternal genome) | Positive (maternal genome present) |
| OCT4 / NANOG | Negative | Positive (germ cell origin) |
| SALL4 | Negative | Positive |
| CD10 | Positive (both) | Positive (both) |
p57KIP2 and OCT4/SALL4 are the most useful IHC markers to separate the two entities.
5. Serum Markers
- Beta-hCG is elevated in both - not helpful for distinction
- However, in gestational type, hCG levels tend to be extremely high and fall rapidly with chemotherapy
- In non-gestational, hCG may be lower and falls more slowly
Summary Algorithm
Choriocarcinoma on histology
↓
History of recent pregnancy / molar disease?
↓
YES → Likely Gestational → Confirm with STR genotyping
NO → Likely Non-Gestational
↓
IHC: OCT4/SALL4 positive? → Non-gestational (germ cell origin)
↓
STR analysis → Absence of paternal alleles = CONFIRMS Non-gestational
Why This Distinction Matters Critically
| Gestational | Non-Gestational | |
|---|---|---|
| Chemo regimen | EMA-CO (methotrexate + actinomycin D based) | BEP (bleomycin, etoposide, cisplatin) |
| Prognosis | Excellent - ~100% cure rate even with metastases | Poor - aggressive, chemoresistant |
| Fertility | Often preserved after chemo | Usually lost (TAH-BSO already done here) |
| Monitoring | Serial beta-hCG | Serial beta-hCG + imaging |
In this patient's case (39F, TAH-BSO for fibroid, no mention of recent pregnancy), STR genotyping and OCT4/SALL4 IHC should be performed. Given no stated pregnancy history and the ovary being the primary site, non-gestational choriocarcinoma is more likely - but must be confirmed before choosing chemotherapy.
- Robbins, Cotran & Kumar Pathologic Basis of Disease, Gestational Trophoblastic Disease, p.957-958
- Berek & Novak's Gynecology, Choriocarcinoma of the Ovary, p.2395
- Sait HK et al., Cureus 2024 [PMID: 39246853]
This is a shared conversation. Sign in to Orris to start your own chat.